A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3732-3738

  Janoly Dumenil, Audrey ^a   Rouvet, Isabelle ^b   Bleyzac, Nathalie ^b   Morfin, Florence ^b   Zabot, Marie Therese ^b   Tod, Michel ^c,d  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; IN VITRO STUDY; LYMPHOBLASTOID CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, THEORETICAL;

EID: 84862557083     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06423-11     Document Type: Article

References (30)

1. Atkinson K, et al. 1995. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant. 16:401-405.
2. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2009. NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City, MD.
3. Boeckh M, et al. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88:4063-4071.
4. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036-2049.
5. Dahari H, Lo A, Ribeiro RM, Perelson AS. 2007. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J. Theor. Biol. 247:371-381.
6. Duan J, et al. 1998. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 39:189-197.
7. Einsele H, et al. 2000. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 25:757-763.
8. Einsele H, et al. 2006. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107:3002-3008.
9. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. 1999. The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. 190:177-182.
10. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. 2002. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J. Infect. Dis. 185:1723-1728.
11. Forman SJ, Zaia JA. 1994. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 83:2392-2398.
12. Herz AV, Bonhoeffer S, Anderson RM, May RM, Nowak MA. 1996. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc. Natl. Acad. Sci. U. S. A. 93:7247-7251.
13. Holberg-Petersen M, et al. 1996. Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro. Blood 88:2510-2516.
14. Lischka P, et al. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.
15. Matthews T, Boehme R. 1988. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3):S490-S494.
16. McGavin JK, Goa KL. 2001. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61:1153-1183.
17. Mori T, et al. 2002. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 29:777-782.
18. Najioullah F, Thouvenod D, Lina B. 2001. Development of a real time PCR procedure including an internal control for the measurement of HCMV viral load. J. Virol. Methods 92:55-64.
19. Neitzel H. 1986. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum. Genet. 73:320-326.
20. Ouellet D, et al. 2009. The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment. Clin. Pharmacol. Ther. 85:277-282.
21. Perrottet N, et al. 2009. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet. 48:399-418.
22. Saleh AJ, et al. 2010. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. Hematol. Oncol. Stem Cell Ther. 3:116-120.
23. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. 1997. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90:2502-2508.
24. Shannon-Lowe CD, Emery VC. 2010. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 1:4.
25. Sommadossi JP, Carlisle R. 1987. Toxicity of 3′-azido-3′- deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31:452-454.
26. Stocchi R, et al. 1999. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant. 23:705-709.
27. Tomonari A, et al. 2004. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann. Hematol. 83:573-577.
28. Torre-Cisneros J, et al. 2010. Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients. Enferm. Infecc. Microbiol. Clin. 28:6-12.
29. Wolfe EJ, et al. 1997. Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 17:591-598.
30. Yano Y, Beal SL, Sheiner LB. 2001. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28:171-192.